Jackson ImmunoResearch launches new antibodies and conjugates

GFP is a common fusion protein tag that enables protein expression to be monitored, quantified, and localized within the complex environment of the cell

Oblique Therapeutics and Eli Lilly to apply the AbiProt technology to generate antibodies to a high-value target

This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties

Biotium introduces novel antibody labeling Kits for efficient labeling of IgM antibodies

Mix-n-Stain CF Dye IgM Antibody Labeling Kits address longstanding challenges for labeling IgM antibodies by offering efficient and convenient conjugation with bright CF Dyes

Biotium introduces new line of antibodies for exosome detection

ExoBrite antibody conjugates are validated and optimized for bright and specific detection of exosome markers

Study shows Moderna vaccine maintains antibodies against Variants of Concern and Interest

Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose

Novavax announces COVID-19 vaccine booster data indicating four-fold increase in neutralising antibodies

Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series

Zydus seeks DCGI approval for monoclonal antibodies cocktail

Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants

Celonic and Carbogen Amcis partner to deliver ADC development and manufacturing platform

Molcure and Boehringer Ingelheim team up to supercharge antibody discovery with AI

This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery

Moderna’s mNEXSPIKE generates strong immune response against LP.8.1 variant in humans

Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains